ProShares Ultra Nasdaq BiotechnologyBIB:NMQ:USD

Add to portfolio
Compare
Interactive chart
Historical prices
View PDF
100.18
1.88 / 1.91%
43.76 - 107.04+1.24
Close in USDToday's change52-week range3-yr sharpe ratio
As of May 17 2013 20:59 BST.Data delayed by at least 15 minutes.

Trailing total returns

5 years3 years1 year6 months3 months1 month
ProShares Ultra Nasdaq Biotechnology
Fund
--+45.52%+82.93%+67.52%+38.53%+15.23%
Trading-Leveraged Equity
Morningstar category
+1.36%+14.17%+27.68%+31.27%+10.09%+2.98%
NASDAQ Biotechnology TR USD
Benchmark index
------------
Fund quartile--1st1st1st1st1st
Funds in category245572777777
As of Apr 30 2013.

Trailing returns analysis

The chart shows how frequently the fund's 3-month return is positive or negative. Each bar is an observation period (the fund's return over the past 3 months, at month's end).
Best & worst 3 month trailing return since inceptionRate of return
January 2013 - April 2013
+38.51%
June 2011 - September 2011
-26.43%
As of Apr 30 2013.

The performance data shown in tables and graphs on this page is calculated in USD of the fund / index / average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.

All managed funds data located on FT.com is subject to the FT Terms & Conditions . All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2013
All Rights reserved

© 2013 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.